Mickey Flynn to Step Down as President of Pennsylvania Bio Mid-Year, Board Names Chris Molineaux His Successor

Mickey Flynn to Step Down as President of Pennsylvania Bio Mid-Year, Board Names Chris Molineaux His Successor     
Malvern, PA, February 2, 2010 - The Board of Directors of Pennsylvania Bio announced today that Dennis M. "Mickey" Flynn will step down as president of the association on June 30, 2010, and named Christopher Molineaux, senior vice president of Pennsylvania Bio, as Flynn's successor.
To facilitate a seamless leadership transition, Flynn will continue to serve the association for the remainder of 2010 as vice chairman of the Board of Directors and a member of the Executive Committee.  Molineaux will continue in his role as senior vice president for membership services and begin over the next five months to transition into broader operational responsibilities of the association.

Flynn is a founder of Pennsylvania Bio, the trade association for the bioscience industry in Pennsylvania, and served as a Board member and chairman before assuming the role of president of the association in November 2005. "Mickey Flynn has been a tireless advocate for our industry and an outstanding president of our association.  For more than 30 years, Mickey has been a leader in our community and most recently succeeded in making Pennsylvania Bio one of the largest and most effective trade associations in the country for our industry," said Steven Nichtberger, M.D., Pennsylvania Bio chairman and president and CEO of Tengion, Inc.  

Flynn has grown the organization to more than 375 members in his four years as president of the association, making Pennsylvania Bio one of the largest state-level trade associations for the bioscience industry in America. 

"Through growth in programs and group purchasing opportunities for members, as well as extraordinary advocacy efforts in Harrisburg and Washington, DC, Mickey Flynn's leadership at Pennsylvania Bio has had a tremendous impact on bioscience companies in the Commonwealth of Pennsylvania," said Julie McHugh, vice chair of Pennsylvania Bio's Board.  "We are fortunate to have someone of Chris Molineaux's caliber and experience succeed Mickey as president of Pennsylvania Bio and are confident that he is the right person to lead our association to an even greater level of success in the new decade."

Molineaux joined Pennsylvania Bio in September 2009 from Johnson & Johnson, where he most recently served as worldwide vice president of pharmaceutical communication & public affairs.  He began his Johnson & Johnson career as vice president of corporate communications at Centocor in Malvern. Molineaux brings to Pennsylvania Bio more than 18 years of experience in health care policy and advocacy, including industry and payor community expertise. He served as vice president of public affairs at the Pharmaceutical Research and Manufacturers Association (PhRMA), and for seven years prior to this, he worked with the Blue Cross and Blue Shield Association in roles of increasing responsibility in communications and policy. Molineaux also worked as a public affairs executive for both the federal Departments of Health and Human Services (HHS) and Agriculture.

"Throughout Pennsylvania, the biosciences are a cornerstone of our commonwealth's economic future. The industry is responsible for more than 77,000 direct jobs and an economic impact in the tens of billions of dollars, making Pennsylvania a national leader in the development and sales of innovative products to patients in need.  I am proud to support the continued growth of the biosciences in our state and will work to ensure that Pennsylvania Bio continues to provide world-class services and advocacy to assist in the success of our member companies," said Molineaux. "I look forward to expanding on Mickey's wonderful legacy."

"I am honored to have spent my career in an industry that is dedicated to improving the lives of people," said Mickey Flynn.  "Serving as president of Pennsylvania Bio has in many ways been a wonderful capstone to my time in this industry. I am particularly proud to have worked with so many bioscience companies and dedicated professionals focused on providing new therapies for patients who suffer with health issues for which there is no help, but fortunately through medical advancements made by many of our member companies, there is now hope. Chris Molineaux has the experience and vision necessary to be an outstanding president of Pennsylvania Bio, and I look forward to working with him to ensure a successful transition."

About Pennsylvania Bio
Pennsylvania Bio is a catalyst to ensure Pennsylvania is a global leader in biosciences by developing a cohesive community that unites the region's biotechnology, pharmaceutical, medical device, diagnostic, research, and financial strengths.

Suggested Articles

Shorla Pharma picked up $8.3 million to push its cancer programs through U.S. regulatory approval and gear up for its first drug launch in 2021.

Nodthera bagged $55 million to get its lead asset through phase 1 and into proof-of-concept studies, and a second program into the clinic.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.